
Opinion|Podcasts|October 26, 2023
Protecting Cardiorenal Function in Diabetic Kidney Disease
Listen
0:00 / 0:00
Experts discuss the intricate relationship between diabetes, kidney disease, and cardiovascular function and explore the evolving landscape of therapies with cardiorenal benefits.
Advertisement
1:27 Diabetes, kidney disease, and CV risk interrelationship
3:54 Expanding indications for SGLT2 inhibitors for CV risk reduction
5:40 CV benefits of SGLT2 inhibitors in clinical trials
7:20 Use of finerenone for CKD
9:20 Using stage and severity of CKD to guide treatment choice
14:00 Benefits of combining finerenone with SGLT2 inhibitors
16:30 Potential use of GLP 1 agonists for CKD
19:20 Considerations for incorporating therapies for CKD
23:00 Key takeaways on using new treatments for CKD
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Kidney Compass: VISIONARY 2-Year eGFR Data in IgA Nephropathy
2
Bimekizumab Data Support Case for Earlier Intervention in HS
3
A Genetic Signature May Predict Who Gets Sick From CAR T Cell Therapy
4
Rethinking HFpEF Screening and Care, With Ronald D'Agostino, DO
5







































































